Screener
Ginkgo Bioworks DNA Reportable Segment — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|---|---|
| Revenue | $20,156 | $39,134 | $39,630 | $77,364 |
| Costs and operating expenses: | ||||
| Cost of other revenue (1) | 1,472 | 3,865 | 4,144 | 6,986 |
| Research and development (1) | 30,433 | 31,065 | 60,538 | 79,735 |
| General and administrative (1) | 11,108 | 15,986 | 23,831 | 35,639 |
| Stock-based compensation (2) | 8,037 | 18,770 | 24,745 | 36,483 |
| Depreciation and amortization | 12,315 | 15,249 | 25,114 | 30,071 |
| Restructuring charges (3) | — | 3,566 | — | 8,032 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's reportable segment — R&D?
- Ginkgo Bioworks (DNA) reported reportable segment — R&D of $30.43M in Q2 2026.
- What does reportable segment — R&D mean?
- This reflects the expenditures dedicated to innovation, technology development, and the advancement of proprietary platforms within a specific segment. It is a critical measure of the company's commitment to long-term competitive advantage and future product pipeline development.
Ask your AI about Ginkgo Bioworks's reportable segment — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude